Related Experiment Video
Updated: Mar 16, 2026
09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
8.0K
MicroRNA-328, a Potential Anti-Fibrotic Target in Cardiac Interstitial Fibrosis.
Weijie Du1, Haihai Liang, Xu Gao
1Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), Harbin Medical University, Harbin, P. R. China.
Summary
MicroRNA-328 (miR-328) promotes cardiac fibrosis by targeting TGFβRIII, leading to increased collagen production. Inhibiting miR-328 reduced fibrosis in mouse models, suggesting its role in heart disease.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Fibrosis Research
Background:
- Deregulated myocardial fibrosis is a key factor in various heart conditions.
- MicroRNAs play crucial roles in regulating cardiac function and disease progression.
Purpose of the Study:
- To investigate the role of microRNA-328 (miR-328) in the regulation of cardiac fibrosis.
- To elucidate the molecular mechanisms underlying miR-328's function in the heart.
Main Methods:
- Cardiac fibrosis induced by myocardial infarction (MI) in C57BL/6 mice.
- Quantification of miR-328 levels using real-time PCR.
- Assessment of fibrosis via Masson's Trichrome staining.
- Analysis of protein expression (TGFβRIII, TGF-β1) using Western blot.
Main Results:
- miR-328 was upregulated in infarcted mouse hearts, correlating with increased cardiac fibrosis.
- miR-328 targeted and downregulated TGFβRIII, while upregulating TGF-β1 signaling and collagen production.
- Inhibition of miR-328 using antisense oligonucleotides significantly reduced cardiac fibrosis.
Conclusions:
- miR-328 acts as a pro-fibrotic microRNA in the context of heart disease.
- Targeting miR-328 presents a potential therapeutic strategy for mitigating cardiac fibrosis.
